Ambev S.A. (0A6X)
London Exchange · UK · prices in USD · close of 23 Oct 2026
Key indicators
| Last close | USD 3.320 |
|---|---|
| 52-week range | 2.180 – 3.500 |
| Return, 1 month / 3 months | +11.3% / +6.7% |
| Return, 1 year / 3 years | +56.3% / +61.1% |
| Trend | Uptrend |
| RSI (14) | 65 |
| Volatility (1 year) | 35.7% |
| Worst drawdown (1 year) | -17.8% |
| Average daily value traded | 0.05M USD |
| Dividend yield | 0.8% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Ambev is a beverage company based in Brazil that brews and distributes beer and produces soft drinks, bottled water and other non-alcoholic drinks. Its beer brands include Skol, Brahma and Antarctica, and it also makes malt-based and ready-to-drink products. The company serves consumers across Brazil and other countries in Latin America through a large network of distributors, bars, restaurants and retailers, and it is part of the Anheuser-Busch InBev group.
On this site Ambev S.A. appears as a stock on the London Exchange (UK), code 0A6X, with prices in US dollars (USD). Our dividend records, which start in 2019, show payments in 6 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Ambev S.A. (0A6X) trades on the London Exchange in UK. It last closed at USD 3.320 on 23 October 2026.
Its price-based Market X-Ray is 61 out of 100 (a fair price profile), ranking 1,254 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 56.3% and over the last three months it rose 6.7%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 70 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 9.7% | ||
| From 52-week high | -3.6% | ||
| Momentum | 76 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 6.7% | ||
| 6-month return | 11.7% | ||
| 12-month return, skipping the last month | 40.4% | ||
| Stability (higher is calmer) | 64 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 35.7% | ||
| Worst drawdown, 1 year (smaller is calmer) | -17.8% | ||
| Liquidity | 23 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.05M USD | ||
| Zero-volume days | 0.0% | ||
| Income | 49 · Weak | Dividend is small or irregular. | |
| Dividend yield | 0.8% | ||
| Years with dividends | 6 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
Weak spots
- Liquidity: Thinly traded: prices can jump and exits can be hard.
- Income: Dividend is small or irregular.
Returns
| 1 week | +1.6% |
|---|---|
| 1 month | +11.3% |
| 3 months | +6.7% |
| 6 months | +11.7% |
| 1 year | +56.3% |
| 3 years | +61.1% |
| 5 years | +65.9% |
Signals
| 50-day / 200-day average | 3.046 / 3.026 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.097 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 23 Sep 2026 | BRL 0.0087 |
| 24 Jun 2026 | BRL 0.0057 |
| 22 Dec 2025 | BRL 0.1258 |
| 11 Aug 2025 | BRL 0.0230 |
| 19 May 2025 | BRL 0.0219 |
| 18 Mar 2025 | BRL 0.0221 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.